Amyloid imaging, used to detect plaques in the brain, may help diagnose cardiac amyloidosis, researchers said.
Amyloid imaging may help diagnose cardiac amyloidosis, say researchers in an article in the Journal of Nuclear Medicine. Amyloid imaging is currently used to detect plaques in the brain.
There is no noninvasive imaging test to diagnose cardiac amyloidosis, which is associated with a high mortality. Early diagnosis is essential, before structural change to the heart tissue has occurred. Echocardiography is used to image cardiac amyloidosis, but a cardiac biopsy is needed to confirm diagnosis.
Researchers from Sweden undertook a small study using PET with 11C-PIB to visualize amyloid deposits in the heart. The group comprised 10 patients, who had been diagnosed with cardiac amyloidosis, and five healthy subjects. They all underwent PET/CT with 11C-PIB, and 11C-acetate was used to measure myocardial blood flow.
Researchers noted an obvious uptake of 11C-PIB in the left ventricle wall of all the cardiac amyloidosis patients, but not in any healthy subject. The agent was also found in the right ventricle wall of half the patients, and nine patients had signs of reversible uptake, with a maximum concentration of 10 to 15 minutes after injection.
Myocardial blood flow was significantly lower in the cardiac amyloidosis patients, but no significant correlation was found between myocardial blood flow and 11C-PIB.
“This study emphasizes the strength of molecular imaging for detecting an underlying and significant molecular aberration in a disease that presents with unspecific symptoms and signs,” lead author, Gunnar Antoni, PhD, said in a press release. Antoni is from the PET Centre at Uppsala University Hospital, in Uppsala, Sweden. “The potential for molecular imaging to provide valuable information for other diseases is of great value to the field of medicine.”
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.